Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years (Q37327047)
Jump to navigation
Jump to search
scientific article published on 14 May 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years |
scientific article published on 14 May 2009 |
Statements
1 reference
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years (English)
1 reference
Vicki Seyfert-Margolis
1 reference
Jennifer Puck
1 reference
Kevan C Herold
1 reference
Carla Greenbaum
1 reference
Stephen Gitelman
1 reference
William Hagopian
1 reference
Peter Gottlieb
1 reference
Peter Sayre
1 reference
Peter Bianchine
1 reference
Emelita Wong
1 reference
Kasia Bourcier
1 reference
Jeffrey A Bluestone
1 reference
Immune Tolerance Network ITN007AI Study Group
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference